Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP8232 add-on therapy for albuminuria reduction in type 2 diabetes and chronic kidney disease
2014-002349-23Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis, chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) comparing ASP8232 add-on with Placebo add-on (2 arms). Primary endpoint: Mean change of log-transformed urinary albumin to creatinine ratio from baseline to end of treatment. Started Oct 2014; status: completed.
02
Drugs
ASP8232
03
Conditions
diabetic glomerulosclerosischronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-002349-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002349-23.